Heungsup Sung

Heungsup Sung

Auto-generated profile, based on publicly available information

Heungsup Sung

Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
KHKi Ho Hong
Ki Ho Hong
SLSang Won Lee
Sang Won Lee
TKTaek Soo Kim
Taek Soo Kim
HHHee Jae Huh
Hee Jae Huh
JLJaehyeon Lee
Jaehyeon Lee
CYCheon Kwon Yoo
Cheon Kwon Yoo
The outbreak of coronavirus disease 2019 (COVID-19), which began in December 2019, is still ongoing in Korea, with >9,000 confirmed cases as of March 25, 2020. COVID-19 is a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, and real-time reverse transcription-PCR is currently the most reliable diagnostic method for COVID-19 around the world. Korean Society for Laboratory Medicine and the Korea Centers for Disease Prevention and Control propose guidelines for diagnosing COVID-19 in clinical laboratories in Korea. These guidelines are based on other related domestic and international guidelines, as well as expert opinions and include the selection of test subjects, selection of specimens, diagnostic methods, interpretation of test results, and biosafety.

1 April 2013 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
HKHyun-Ki Kim
Hyun-Ki Kim
SOSung-Hee Oh
Sung-Hee Oh
KYKyung Ah Yun
Kyung Ah Yun
HSHeungsup Sung
Heungsup Sung
MKMi-Na Kim
Mi-Na Kim
A novel multiplex real-time PCR approach (Anyplex II RV16 [RV16]; Seegene, South Korea) was compared with a multiplex endpoint PCR kit (Seeplex RV15 ACE detection kit [RV15]; Seegene) and a liquid bead-based assay (xTAG respiratory viral panel [xTAG]; Abbott, United States). Of nasopharyngeal swabs or aspirates and bronchoalveolar lavage fluid samples submitted for RV15 testing, 199 retrospectively collected positive specimens and 283 prospectively collected specimens were further tested with RV16 and xTAG. A true-positive result was defined as a positive result from all three methods or RV16 and xTAG or RV15 and xTAG. For specimens with discrepant results, monoplex PCR and sequencing of the target viruses were performed. In total, 300 virus-positive specimens yielded 386 viruses. When the bocavirus results were excluded, the overall sensitivities of RV16, RV15, and xTAG were 95.2%, 93.3%, and 87.2%, respectively (95% confidence intervals, 93.0 to 97.4%, 90.8 to 95.8%, and 83.8 to 90.6%, respectively). RV16 was more sensitive than xTAG for coronavirus OC43/HKU1 (100% versus 26.1%; P < 0.0001) and adenovirus (100% versus 79.5%; P < 0.01) but was less sensitive than xTAG for rhinovirus/enterovirus (89.4% versus 97.9%; P < 0.05). RV16 demonstrated higher sensitivity than RV15 for the detection of adenovirus (100% versus 82.1%; P < 0.05). The specificities of all three methods ranged from 98.6% to 100%. Sequencing analysis of 64 rhinovirus-positive samples revealed that RV16 accurately differentiated between rhinovirus and enterovirus. RV16 most frequently missed rhinovirus C. In conclusion, the overall sensitivity of RV16 was better than that of xTAG. However, improvement of the sensitivity for rhinovirus is required.

1 January 2017 in Korean Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
ELEun Lee
Eun Lee
HCHyun-Ju Cho
Hyun-Ju Cho
SHSoo-Jong Hong
Soo-Jong Hong
JLJina Lee
Jina Lee
HSHeungsup Sung
Heungsup Sung
JYJinho Yu
Jinho Yu
Macrolide resistance rate of Mycoplasma pneumoniae has rapidly increased in children. Studies on the clinical features between macrolide susceptible-M. pneumoniae (MSMP) and macrolide resistant-M. pneumoniae (MRMP) are lacking. The aim of this study was to identify the macrolide resistance rate of M. pneumoniae in Korean children with M. pneumoniae penupmonia in 2015 and compare manifestations between MSMP and MRMP. Among 122 children (0-18 years old) diagnosed with M. pneumoniae pneumonia, 95 children with the results of macrolide sensitivity test were included in this study. Clinical manifestations were acquired using retrospective medical records. The macrolide resistant rate of M. pneumoniae was 87.2% (82 of 94 patients) in children with M. pneumoniae pneumonia. One patient showed a mixed type of wild type and A2063G mutation in 23S rRNA of M. pneumoniae. There were no significant differences in clinical, laboratory, and radiologic findings between the MSMP and MRMP groups at the first visit to our hospital. The time interval between initiation of macrolide and defervescence was significantly longer in the MRMP group (4.9±3.3 vs. 2.8±3.1 days, P=0.039). The macrolide resistant rate of M. pneumoniae is very high in children with M. pneumoniae pneumonia in Korea. The clinical manifestations of MRMP are similar to MSMP except for the defervescence period after administration of macrolide. Continuous monitoring of the occurrence and antimicrobial susceptibility of MRMP is required to control its spread and establish strategies for treating second-line antibiotic resistant M. pneumoniae infection.

1 August 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
RJRohan P. Joshi
Rohan P. Joshi
VPVikas Pejaver
Vikas Pejaver
NHNoah E. Hammarlund
Noah E. Hammarlund
HSHeungsup Sung
Heungsup Sung
SLSeong Kyu Lee
Seong Kyu Lee
NBNiaz Banaei
Niaz Banaei

1 October 2020 in Emerging Infectious Diseases
Verified
Journal Article
Closed access
HSHeungsup Sung
Heungsup Sung
MHMyung-Guk Han
Myung-Guk Han
CYCheon-Kwon Yoo
Cheon-Kwon Yoo
SLSang-Won Lee
Sang-Won Lee
Yoon-Seok ChungYoon-Seok Chung
Yoon-Seok Chung
WMWon-Ki Min
Won-Ki Min
External quality assessment (EQA) is essential for ensuring reliable test results, especially when laboratories are using assays authorized for emergency use for newly emerging pathogens. We developed an EQA panel to assess the quality of real-time reverse transcription PCR assays being used in South Korea to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the participation of 23 public health organization laboratories and 95 nongovernmental laboratories involved in SARS-CoV-2 testing, we conducted qualitative and semiquantitative performance assessments by using pooled respiratory samples containing different viral loads of SARS-CoV-2 or human coronavirus OC43. A total of 110 (93.2%) laboratories reported correct results for all qualitative tests; 29 (24.6%) laboratories had >1 outliers according to cycle threshold values. Our EQA panel identified the potential weaknesses of currently available commercial reagent kits. The methodology we used can provide practical experience for those planning to conduct evaluations for testing of SARS-CoV-2 and other emerging pathogens in the future.

1 September 2020 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YKYoung-Jin Kim
Young-Jin Kim
HSHeungsup Sung
Heungsup Sung
CKChang-Seok Ki
Chang-Seok Ki
Mina HurMina Hur
Mina Hur
M.M.D.
M.D.
PHPh.D.
Ph.D.
Young Jin Kim, M.D., Ph.D., Heungsup Sung, M.D., Ph.D., Chang-Seok Ki, M.D., Ph.D., and Mina Hur, M.D., Ph.D.. Ann Lab Med 2020;40:349-50. https://doi.org/10.3343/alm.2020.40.5.349